PRF Technologies Ltd.
PRF Technologies is an Israel-based specialty pharmaceutical company focused on reformulating established therapeutics with extended-release drug-delivery systems. Its drug development business combines generic drugs with its delivery technology. OcuRing™-K is a sustained-release ocular device designed to deliver ketorolac after cataract surgery, while OcuRing™ is a bio-erodible implant applied to an intraocular lens and designed to release medications for postoperative care. PRF-110 is a ropivacaine-based solution designed for extended local pain relief after surgery; development activities on it have been scaled back, and it is no longer the company’s primary clinical focus. PRF Technologies also acquired the business operations related to DeepSolar, an AI-driven solar analytics technology, in March 2025. The company is headquartered in Tel Aviv, Israel. It has not established commercial organization or distribution capabilities and contracts with third parties for manufacturing certain product candidates and clinical trial materials.
No SEC Form 4 filings for $PRFX in the last 30 days.
See all $PRFX insider activity →PRF Technologies (PRFX) announced a Dec. 21, 2026, annual meeting to vote on a 5-for-1 reverse stock split, increasing authorized shares, and other corporate actions. S.H.N. Financial, holding 5.7% of voting rights, demanded a special meeting to remove directors, which the company rejected. Spark's AI Analyst rates PRFX as Neutral due to weak financials and technical indicators.
PRF Technologies (NASDAQ:PRFX) received a delisting notice from Nasdaq after its share price fell below $1.00 for 30 days. The company requested a hearing, which suspends the delisting process. PRF Technologies plans to present a compliance plan, possibly including another reverse stock split. The company reported $11.0 million in cash and short-term deposits as of September 30, 2026, and is working on a transaction with Dotz.
PRF Technologies (PRFX) and Dotz Nano (DTZ) signed a term sheet for a strategic collaboration. Dotz will license and acquire PRF's GridFeed AI energy platform for $1.0 million, with PRF taking an equity position in Dotz. The deal aims to expand Dotz's energy optimization offerings by combining GridFeed's renewable energy forecasting and storage optimization with Dotz's AI-driven energy management technologies.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PRFX (PRF Technologies Ltd.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent PRFX coverage spans corporate actions, technology and financial news.
The reverse split could reduce share count and affect liquidity, but the micro‑cap size limits market impact.
The delisting notice creates immediate downside risk for shareholders.
Potential upside for PRFX from equity participation in Dotz; cash inflow improves balance sheet.
Equity raise may dilute existing shareholders while providing cash for trial and GridFeed initiatives.
Product expansion and planned commercial rollout could improve perceived commercialization momentum for PRFX’s DeepSolar platform.
AlphAI scores every news story that mentions PRFX with an AI model for sentiment and relevance, and aggregates insider trades from PRF Technologies Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PRF Technologies (PRFX) announced a Dec. 21, 2026, annual meeting to vote on a 5-for-1 reverse stock split, increasing authorized shares, and other corporate actions. S.H.N. Financial, holding 5.7% of voting rights, demanded a special meeting to remove directors, which the company rejected. Spark's AI Analyst rates PRFX as Neutral due to weak financials and technical indicators.
PRF Technologies (NASDAQ:PRFX) received a delisting notice from Nasdaq after its share price fell below $1.00 for 30 days. The company requested a hearing, which suspends the delisting process. PRF Technologies plans to present a compliance plan, possibly including another reverse stock split. The company reported $11.0 million in cash and short-term deposits as of September 30, 2026, and is working on a transaction with Dotz.
PRF Technologies (PRFX) and Dotz Nano (DTZ) signed a term sheet for a strategic collaboration. Dotz will license and acquire PRF's GridFeed AI energy platform for $1.0 million, with PRF taking an equity position in Dotz. The deal aims to expand Dotz's energy optimization offerings by combining GridFeed's renewable energy forecasting and storage optimization with Dotz's AI-driven energy management technologies.
PRF Technologies (PRFX) reported $11M in cash, $2.5M in liabilities, and a $3.7M operating loss for the nine months ended September 30, 2026. The company raised $10.5M via equity line. Its subsidiary, LayerBio, plans a Phase 2 trial for OcuRing-K. PRFX also aims to spin off GridFeed, an AI-driven renewable energy platform, as a standalone subsidiary.
PRF Technologies (Nasdaq: PRFX) said it expanded its DeepSolar Predict AI platform with “Battery-to-Revenue Intelligence,” adding workflows to optimize battery energy storage revenue using state of charge, constraints, and market conditions. The update follows real-world European validation using market data and is part of progress toward a planned commercial launch and GridFeed trading platform.
PRF Technologies Ltd. (Nasdaq: PRFX) said its DeepSolar unit completed an initial validation of DeepSolar Predict, an AI revenue optimization platform for renewable energy. The validation used real-world European weather, production, and market data across day-ahead and intraday scenarios. The company said this supports its planned commercial launch.
PRF Technologies (Nasdaq: PRFX) said it is advancing DeepSolar Predict, an AI platform aimed at commercial launch to optimize renewable energy revenue. The company says the system combines localized weather forecasting, production forecasting, imbalance risk management, and storage/portfolio optimization with real-time market decision support, building on its NVIDIA Connect participation and a previously filed weather-modeling patent.
PRF Technologies Ltd. (NASDAQ: PRFX) has announced an SEC filing of Form EFFECT, indicating a notice of effectiveness for its F-1 filing. The effectiveness date was May 19, 2026, at 4:30 P.M. The filing impact and sentiment are neutral, and the company has a market cap of $1.29 million.
PRF Technologies has received FDA IND clearance for OcuRing-K, a sustained-release ketorolac ring, allowing it to proceed to a U.S. Phase II clinical trial for post-cataract pain and inflammation. This development, leveraging LayerBio's ocular platform, aims to simplify recovery and improve adherence for cataract surgery patients. The company plans to launch the multi-center trial with patient enrollment targeted for the second half of 2026, advancing its ophthalmic strategy alongside its DeepSolar energy platform.
TEL AVIV, Israel, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- PainReform Ltd. ( Nasdaq: PRFX ) , a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six ...
